immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

GI Innovation is a South Korean bio-venture company, integrating basic science and translational innovation in developing biologics for patients around the world. GI Innovation’s strategic focus is on immuno-oncology and inflammation/immunology diseases. GI Innovation has established GI-SMART platform technology that is designed to accelerate the development of biologics through the efficient optimization of multi-targeting fusion protein therapeutics with high quality and high productivity.

Janssen Vaccines & Prevention BV manufactures and supplies biopharmaceutical products. The company was founded in 2000 and is headquartered in Leiden, the Netherlands.

Oncotherapy science (OTS) is“ to deliver cancer therapeutics and treatments with higher efficacy and fewer side effects to patients suffering from cancer as soon as possible, and to overcome the fight against cancer. Was established with the aim of OTS brought Professor Genomix (Science that handles genetic information systematically) as a pioneer in the medical field with Prof. Atsushi Nakamura (Director, Cancer Precision Medical Research Center, Institute of Cancer, Professor Emeritus, The University of Tokyo, Professor Emeritus of Chicago University) Joint research to identify target molecules suitable for cancer drug development based on comprehensive gene expression analysis, and promote research and development of small molecule drugs, cancer peptide vaccines and antibody drugs for those targets.

Neurymune Biotech Co., Ltd. is a national cancer research center specializing in the development of cancer immunotherapies based on CAR-T cell therapy and a venture company from Yamaguchi University. They aim to be a leading company responsible for the next generation in the field of cancer immunotherapy.

Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Kleo Pharmaceuticals, Inc. is a biotechnology company, which engages in the development of biospecific compounds designed to emulate and enhance the activity of biologics. Its compounds are designed to direct the immune system to destroy cancerous or virally infected cells, and treatment of multiple myeloma and COVID-19. It offers Antibody Recruiting Molecules (ARMs),Synthetic Antibody Mimics (SyAMs), and Monoclonal Antibody Therapy Enhancers (MATEs) pipeline. The company was founded by David A. Spiegel and Roy Prieb in 2015 and is headquartered in New Haven, CT.

Cellectis is a biopharmaceutical company that develops adoptive immunotherapies for cancer. The company’s portfolio includes several lines of proprietary chimeric antigen receptor T-cells targeting individual cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for the treatment of CD19 expressing hematologic malignancies that developed in acute lymphoblastic leukemia and chronic lymphocytic leukemia. The company’s products also include UCART123 for acute myeloid leukemia indications, and UCART38 and UCARTCS1 for multiple myeloma indications.

MacroGenics, Inc., a biotechnology company, focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer, and infectious diseases. The company is developing immune-based products, including monoclonal antibodies; and vaccines to prevent infections in healthy individuals. The company's Fc engineering technology enables to improve antibody functions to eliminate cancer cells. It is also developing products around the Dual Activating ReTargeting technology. The company was founded in 2000 and is headquartered in Rockville, Maryland.

Gliknik, Inc., a biopharmaceuticals company, develops therapies for patients with cancer and immune disorders. Its Immunomodulator Platform involves in off-the-shelf peptide drugs that increase CD4, CD8, and antibody immune responses against cancer; Stradomer Platform produces drugs designed to mimic the eficacy of pooled human intravenous immunoglobulin; and Stradobody Platform produces compounds that are similar to moncolonal antibodies for tumor cell killing. The company was founded in 2007 and is based in Baltimore, Maryland.

I-Mab Biopharma (Shanghai) Co., Ltd. engages in the development of biologics. It focuses on monoclonal antibodies or bi-specific antibodies in the areas of immuno-oncology and autoimmune diseases. The company was founded by Jingwu Zang in March 2017 and is headquartered in Shanghai, China.

Mycoplasma infection is a systemic vasculitis / neuritis, not only with pneumonia, but with various systemic symptoms and clinical course such as asthma, arthritis, nephritis, meningitis, encephalitis, pancreatitis, hepatitis, dermatitis . Symptoms and routine tests are often difficult to distinguish from rheumatic diseases, neurological and psychiatric diseases, blood diseases, chronic inflammatory diseases, and intractable immune diseases.

Sentinext Therapeutics Sdn. Bhd. develops vaccines and therapeutics for tropical infectious diseases. Its pharmaceutical research and development focuses on EV71, polio, influenza and dengue diseases. The company was founded by Mary Jane Cardosa and Peter Samuel Wulff in 2009 and is headquartered in Penang, Malaysia.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

National Cancer Center Korea is a South Korean company located in Goyang-si and ultimately controlled by the Government of South Korea. The firm provides clinical and medical research services.